Innate and T-cellular immune responses to sequential vaccination with chimeric hemagglutinin split influenza virus vaccines in mice.

Kirill Vasilev, Eduard Puente-Massaguer, Irene Hoxie, Kaitlyn Bushfield, Florian Krammer

Abstract read

In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kirill VasilevDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Eduard Puente-MassaguerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Irene HoxieDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Kaitlyn BushfieldDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria. Electronic address: florian.krammer@mssm.edu.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025

$105.4M

NIH HHS 75N93019C00051

6 · The paper itself

Abstract

Chimeric hemagglutinin (cHA)-based vaccines represent a promising strategy toward the development of a broadly protective universal influenza virus vaccine. Previous studies show that sequential administration of cHA split influenza vaccines stimulates broadly cross-reactive antibodies targeting the HA stalk and induces systemic and localized CD4

Indexed as

Hemagglutinin Glycoproteins, Influenza VirusImmunity, CellularImmunity, InnateInfluenza VaccinesOrthomyxoviridae InfectionsT-LymphocytesAdjuvants, ImmunologicAdjuvants, VaccineAnimalsAntibodies, ViralCytokinesFemaleLungMiceMice, Inbred BALB CTh1 CellsAdjuvants, ImmunologicAdjuvants, VaccineAntibodies, ViralCytokinesHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesCpG 1018HA stalkInfluenzaODN 1018T-cellsUniversal vaccine

Identifiers

PMID40876140

DOI10.1016/j.vaccine.2025.127626

PMCPMC13397499

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.